Project TWENTY/21

The Primary Care Cannabis Network is proud to be supporting Project TWENTY21 in association with Drug Science. A medical cannabis registry, with an aim to enrol 20,000 patients by the end of 2021, the project will create evidence to show the effectiveness of medical cannabis as a treatment to complex needs.

Shared care 

Patients have the right to be involved in discussions and make informed decisions about who provides their care and treatment.

 

People’s lives can be transformed when they feel in control of their health and well-being and when they are able to shape their care, support and treatment to fit with what matters to them. When people are involved in decisions about their health and care they tend to choose treatments that align with their personal preferences and goals. 

 

GPs have a legal duty to promote the involvement of people in their own health and should support their patients as much as they want or are able to, in decisions about their care and giving them choice and control over the services they receive. This means focusing on what matters to the individual within the context of their lives.

Patient choice 

When it comes to medical cannabis patients need to know the various options and referral pathways that currently exist within the UK (both within and outside of the NHS).

Currently patients who are not eligible for medical cannabis treatments through the NHS, and who wish to explore medical cannabis as a treatment option for an unmet clinical need, have the choice of a number of private clinics or to enrol themselves within a clinical study. 

NICE and the National Institute for Health Research have recently emphasised the need for further focused research on the therapeutic value of cannabis based medical products. 

Project TWENTY21 

Drug Science, an independent scientific body has launched Europe’s first and biggest national medical cannabis registry, called Project TWENTY21, which sets out to make an important contribution towards addressing the paucity of evidence for the use of cannabis-based medicinal products in all health settings.

TWENTY21 is currently in the process of enrolling 20,000 patients by the end of 2021, creating the largest body of evidence for the effectiveness and tolerability of medical cannabis, using a real-world data. The findings will look at the risk/benefit ratio of medical cannabis in seven key identified conditions for which alternative treatments have failed. Conditions eligible for Twenty21 study:

  • Anxiety Disorder

  • Chronic Pain

  • Epilepsy

  • Multiple Sclerosis (MS)

  • Post Traumatic Stress Disorder (PTSD)

  • Substance Use Disorder (as a harm reduction strategy)

  • Tourette’s Syndrome

Treatment will be provided at a network of private clinics across the UK which utilise best-practice in medical cannabis treatment. 

Project Twenty21 has the support The Royal College of Psychiatrists, The British Pain Society, the United Patients Alliance, patients, peers and medical cannabis campaigners.

Patients can register their interest in the study here.

  • DrugScience.png

    Drug Science launched Europe’s first and biggest national medical cannabis registry, called Project Twenty21, on the 7th November 2019. Drug Science was formed by a committee of scientists with a passionate belief that the pursuit of knowledge should remain free of all political and commercial interest.

  • Twitter
  • LinkedIn

Privacy Policy |  © 2020 Copyright - Medical Cannabis Clinicians’ Society


DISCLAIMER:  All views are those of The Primary Care Cannabis Network. Information on this site is written for the purpose of general education. Information is not specific to any specific medical case and should not be taken to provide a diagnosis or treatment. This material should not be reproduced without the specific permission of the The Primary Care Cannabis Network. The opinions expressed here are of our society and do not necessarily represent the views of any other institutions of which members are affiliated with. The Primary Care Cannabis Network takes no responsibility for any actions taken by individuals in response to the information given here.